II
ADAP

Inspire Investing’s Adaptimmune Therapeutics ADAP Stock Holding History

Inspire Investing’s Portfolio ADAP Stock Details ADAP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-31,928
Closed -$66K – 763
2022
Q1 		$66K Buy
31,928
+11,723
+58% +$31.6K 0.01% 786
2021
Q4 		$76K Buy
+20,205
New +$92K 0.01% 784

Other funds holding ADAP

MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
ECM
Endurant Capital Management San Mateo, California $17.4M AUM 7.38% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Inspire Investing's ADAP Position: Q2 2022 in Review

Inspire Investing sold out of Adaptimmune Therapeutics (ADAP) in Q2 2022, closing a stake of 31,928 shares — an estimated $66K sold.

Inspire Investing first reported a position in ADAP in Q4 2021 and held it in 2 quarters. The position peaked at $76K in Q4 2021. 77 funds tracked by Wall St. Rank hold ADAP as of Q2 2022.

  • Inspire Investing reported no remaining Adaptimmune Therapeutics position as of Q2 2022 after selling out during the quarter.
  • Inspire Investing sold 31,928 Adaptimmune Therapeutics shares in Q2 2022, an estimated $66K.
  • Inspire Investing first reported a position in Adaptimmune Therapeutics in Q4 2021 and held it in 2 quarters.
  • Inspire Investing's Adaptimmune Therapeutics position peaked at $76K in Q4 2021.
  • 77 funds tracked by Wall St. Rank held Adaptimmune Therapeutics as of Q2 2022.

Based on Inspire Investing's 13F filing for Q2 2022, filed 10 Aug 2022.